3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
23
Head & Neck
4
Gynecologic
4
Gastrointestinal
4
Other solid neoplasm
2
Other hematologic neoplasm
1
Genitourinary
1
Dermatologic
1
Conditions
Retinoblastoma
2
Retinal Neoplasms
1
Interventions
pembrolizumab
75
Injections
67
Carboplatin
38
Pemetrexed
29
Cisplatin
29
Nivolumab
27
Specimen Handling
24
Interviews as Topic
24
Cyclophosphamide
24
atezolizumab
21
tislelizumab
20
Bevacizumab
20
Paclitaxel
19
Standard of Care
16
Practice Guidelines as Topic
16
fludarabine
15
Docetaxel
15
toripalimab
14
Ipilimumab
14
Educational Status
14
Cetuximab
14
Fluorouracil
13
Oxaliplatin
12
Etoposide
12
olaparib
11
durvalumab
11
Methods
11
Gemcitabine
11
Early Intervention, Educational
11
Drug Therapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Platinum Compounds
×
Other solid neoplasm
×
1 year
×
Clear all
NCT04681417
2025-11-28
RETINO 2018
Institut Curie
Phase 2/3
Recruiting
225 enrolled
NCT02866136
2025-11-24
RETINO2011
Institut Curie
Phase 2
Active not recruiting
133 enrolled